A patient with gastric cancer and liver metastases successfully treated with combination chemotherapy including S-1

被引:2
作者
Nakamura, Rieko [1 ]
Saikawa, Yoshiro [1 ]
Kumagai, Koushi [1 ]
Kiyota, Tsuyoshi [1 ]
Ohashi, Masaki [1 ]
Yoshida, Masashi [1 ]
Kubota, Tetsuro [2 ]
Kumai, Koichiro [3 ]
Kitajima, Masaki [1 ]
机构
[1] Keio Univ, Sch Med, Dept Surg, Shinjuku Ku, Tokyo 1608582, Japan
[2] Keio Univ, Ctr Comprehens & Adv Med, Tokyo, Japan
[3] Keio Univ, Ctr Diagnost & Therapeut Endoscopy, Tokyo, Japan
关键词
gastric cancer; liver metastases; combination chemotherapy; S-1;
D O I
10.1007/s10147-006-0648-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We report the case of a 62-year-old man with advanced gastric cancer and multiple liver metastases who was successfully treated with combined chemotherapy including S-1. The patient was clinically diagnosed with stage IV (T3 N2 H1 PO) disease and was initially treated with 100mg/body per day S-1 administered orally for 21 days and 10mg/body per day cisplatin (CDDP) infused on days 1-5, 8-12, and 15-19. This chemotherapy resulted in significant reduction of the liver and gastric tumors. After receiving additional CDDP/S-1 administration as an outpatient, the patient's liver masses disappeared as shown on abdominal computed tomography (CT). With the patient's desire and informed consent, he underwent curative surgery with total gastrectomy, D1+alpha lymph node dissection, and partial resection of liver S4. After discharge without any surgical complication, CT revealed regrowth of the S4 liver mass, and combined docetaxel and CDDP was selected as second-line chemotherapy with local radiation therapy against the hepatic metastasis. Additionally, a third regimen with irinotecan and S-I was given. At 2 years 7 months after the initial treatment, no sign of cancer (including liver metastasis and peritoneal dissemination) has been identified by radiological follow-up examinations.
引用
收藏
页码:295 / 299
页数:5
相关论文
共 27 条
  • [21] Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur 0.4 M gimestat 1 M otastat potassium) in advanced gastric cancer patients
    Sakata, Y
    Ohtsu, A
    Horikoshi, N
    Sugimachi, K
    Mitachi, Y
    Taguchi, T
    [J]. EUROPEAN JOURNAL OF CANCER, 1998, 34 (11) : 1715 - 1720
  • [22] Shimada S, 2003, ONCOL REP, V10, P687
  • [23] Stathopoulos GP, 2002, ONCOL REP, V9, P89
  • [24] An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers
    Sugimachi, K
    Maehara, Y
    Horikoshi, N
    Shimada, Y
    Sakata, Y
    Mitachi, Y
    Taguchi, T
    [J]. ONCOLOGY, 1999, 57 (03) : 202 - 210
  • [25] Combination chemotherapy of S-1 and low-dose cisplatin for advanced gastric cancer
    Shunichi Tsujitani
    Kenji Fukuda
    Nobuaki Kaibara
    [J]. Gastric Cancer, 2003, 6 (Suppl 1) : 50 - 57
  • [26] Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European organization for research and treatment of cancer gastrointestinal tract cancer cooperative group
    Vanhoefer, U
    Rougier, P
    Wilke, H
    Ducreux, MP
    Lacave, AJ
    Van Cutsem, E
    Planker, M
    Dos Santos, JG
    Piedbois, P
    Paillot, B
    Bodenstein, H
    Schmoll, HJ
    Bleiberg, H
    Nordlinger, B
    Couvreur, ML
    Baron, B
    Wils, JA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (14) : 2648 - 2657
  • [27] Watanabe Shin, 2002, Int J Clin Oncol, V7, P326